Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 12/20 | 0.58 |
| ▸ | SRC | P12931 | 10/20 | 0.57 |
| ▸ | ABL1 | P00519 | 6/20 | 0.57 |
| ▸ | LCK | P06239 | 5/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | BLK | P51451 | 3/20 | 0.52 |
| ▸ | BTK | Q06187 | 3/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.52 |
| ▸ | FYN | P06241 | 3/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | YES1 | P07947 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | PRKACA | P17612 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | FRK | P42685 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784292 | 0.88 | RET (0.58) | RETSRCABL1LCKEGFR | |
| SCHEMBL19732750 | 0.85 | RET (0.61) | RETSRCABL1LCKEGFR | |
| SCHEMBL3782049 | 0.84 | SRC (0.60) | RETSRCABL1LCKEGFR | |
| SCHEMBL6055060 | 0.80 | RET (0.60) | RETSRCABL1LCKEGFR | |
| SCHEMBL3783622 | 0.78 | RET (0.61) | RETSRCABL1LCKEGFR | |
| SCHEMBL3782929 | 0.78 | SRC (0.58) | RETSRCABL1LCKEGFR | |
| SCHEMBL13019650 | 0.78 | SRC (0.64) | RETSRCABL1LCKEGFR | |
| SCHEMBL13019817 | 0.78 | SRC (0.73) | RETSRCABL1LCKEGFR | |
| SCHEMBL13840242 | 0.77 | RET (0.50) | RETSRCABL1LCKEGFR | |
| SCHEMBL19732743 | 0.77 | SRC (0.58) | RETSRCABL1LCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10981920-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| EP-3269370-A1 | NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2217239-A2 | MODULATION OF PROTEIN TRAFFICKING | Foldrx Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885SRC 153/4885ABL1 99/4885 |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | RET 1/4885SRC 456/4885ABL1 158/4885 |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | RET 1/4885SRC 259/4885ABL1 84/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885SRC 235/4885ABL1 187/4885 |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885SRC 153/4885ABL1 99/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885SRC 153/4885ABL1 99/4885 |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | RET 1/4885SRC 259/4885ABL1 84/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | RET 3063/4885SRC 1332/4885ABL1 1725/4885 |
| US-10981920-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885SRC 146/4885ABL1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.